CAR T-Cell Therapy
UI Health is an approved treatment site for CAR (Chimeric Antigen Receptor) T-Cell Therapy. This is an FDA-approved therapy for treating specific types of lymphoma, leukemia, and multiple myeloma in patients who have not responded to previous cancer treatments. Studies have shown CAR-T cell therapy offers excellent results for people with specific blood cancers where previous treatments didn’t work. This therapy provides a new avenue for combating cancer, potentially leading to improved survival and quality of life. CAR-T cell therapy works by attacking and killing cancer in the body by adapting millions of your own immune system cells.
Who Can Receive This Treatment?
CAR-T Cell Therapy is not the same as a stem cell transplant or chemotherapy. CAR-T therapy may be a treatment option for:
- Relapsed, refractory B-cell acute lymphoblastic leukemia
- Relapsed, refractory B-cell Non-Hodgkin’s lymphoma
- Relapsed, refractory mantle cell lymphoma
- Relapsed, refractory follicular lymphoma
- Relapsed, refractory multiple myeloma
How it Works
CAR-T therapy works by:
- Extracting T-cells or white blood cells from your blood
- Modifying and duplicating T-cells in the lab
- Reintroducing CAR-T cells back into your body where they will travel throughout the body looking for cancer cells
- Millions of CAR-T cells detect and kill cancer cells
- Most people have a reaction to CAR-T cells that requires them to stay in the hospital for days to weeks for monitoring and management.
